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ORIGINAL ARTICLE
Health care resource utilization and costs of California Medicaid patients with
schizophrenia treated with paliperidone palmitate once monthly or atypical
oral antipsychotic treatment
Jacqueline A. Pesaa, Dilesh Doshia, Li Wangb, Huseyin Yucec and Onur Baserd,e
aJanssen Scientific Affairs, Titusville, NJ, USA; bSTATinMED Research, Plano, TX, USA; cNew York City College of Technology, Brooklyn, NY,
USA; dSTATinMED Research, New York, NY, USA; eCenter for Innovation & Outcomes Research, Columbia University, New York, NY, USA
ABSTRACT
Objective: To compare all-cause health care utilization and costs between patients with schizophrenia
treated with once monthly paliperidone palmitate (PP1M; Invega Sustenna1) and atypical oral anti-
psychotic therapy (OAT).
Methods: This was a retrospective claims-based analysis among adult California Medicaid (Medi-Cal)
patients with schizophrenia having 2 claims for PP1M or OAT from 1 July 2009 to 31 December 2013
and continuous health plan enrollment for 1 year pre- and post-index date (PP1M or OAT initiation
date). Baseline characteristics were reported descriptively. Propensity score matching with a 1:1 greedy
match method was used to create two matched cohorts. Treatment patterns, all-cause health care util-
ization, and costs for the 12 month follow-up period were compared between the two matched
cohorts.
Results: Two well matched cohorts of 722 patients were produced with similar baseline characteristics.
During the 12 month follow-up period, PP1M patients were significantly less likely to discontinue treat-
ment (30.6% vs. 39.5%, p< .001) or switch to a new therapy (21.6% vs. 27.7%, p¼ .007). PP1M patients
had fewer inpatient visits (5.0 vs. 7.9, p< .001), lower mean hospitalization days (15.0 vs. 27.7 days,
p< .001) and inpatient costs ($5060 vs. $10,880, p< .001). While pharmacy costs were significantly
higher in the PP1M cohort ($16,347 vs. $9115, p< .001), total costs were not significantly different
between the matched cohorts ($25,546 vs. $25,307, p¼ 0.853).
Conclusions: Patients with schizophrenia treated with PP1M had significantly fewer inpatient hospital-
izations and associated costs with no significant difference in the total costs between the two cohorts.
This study is subject to limitations associated with claims data such as miscoding, inability to examine
clinical severity, etc.
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Introduction
Schizophrenia is a chronic, disabling mental disorder that
affected at least 21 million patients worldwide in 20111. The
peak ages of onset are 20–28 years for men and 26–32 years
for women2,3. According to the Global Burden of Disease
study, schizophrenia accounts for 1.1% of the total disability-
adjusted life years (DALYs)4. In 2002, the overall cost of
schizophrenia was estimated to be $62.7 billion, with $30.3
billion accounting for total direct costs and $32.4 billion
indirect costs5. One-third to two-thirds of total direct health
care costs are associated with inpatient hospital care due to
relapses and re-hospitalizations, indicating that this disease
imposes a significant clinical and economic burden on
patients, payers, and society6.
Antipsychotic drugs form the cornerstone of treatment
among patients with schizophrenia in reducing the severity
and frequency of acute relapse episodes6–8. Several drugs,
including the atypical antipsychotics (risperidone [Risperdal
Consta2], olanzapine [Zyprexa Relprevv3], aripiprazole
[Abilify4], paliperidone palmitate [Invega Sustenna]) and typ-
ical antipsychotics (haloperidol [Haldol5], fluphenazine
[Prolixin5]), are available as oral antipsychotics (OATs) and/or
long-acting injectables (LAIs)9. Atypical antipsychotics are
associated with fewer extra-pyramidal side effects compared
to the typical antipsychotics and are therefore the first-line
therapeutic agents of choice6,10. In practice, non-adherence
to OATs is a frequent challenge and common cause of
relapse, re-hospitalizations, increased symptom severity, lon-
ger inpatient stays, and higher hospital costs in patients with
schizophrenia6. A study examining medication continuity in
Medicaid beneficiaries diagnosed with schizophrenia sug-
gested that only 61% of Medicaid-covered patients regularly
refilled their antipsychotic drug prescriptions, which suggests
that there is an opportunity to improve medication adher-
ence in this population11. According to a previous study con-
ducted by Weiden et al., California Medicaid (Medi-Cal)
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patients who did not adhere to the prescribed antipsychotic
therapy were at an increased hospitalization risk, leading to
higher health care costs12. It has also been observed that less
than 12% of Medi-Cal patients with schizophrenia receive
uninterrupted antipsychotic therapy, leading to a high rate of
relapse and higher health care burden13. The Medi-Cal popu-
lation is composed mainly of low-income and disabled
patients. With a disproportionately high prevalence of schizo-
phrenia among the Medi-Cal population14, the pervasive
challenge of antipsychotic non-adherence may lead to
increased hospitalizations and health care costs.
According to recent guidelines, LAIs may help patients with
schizophrenia to overcome non-adherence compared to oral
antipsychotics; LAIs have also been associated with reduced
relapse episodes and lower rates of re-hospitalizations6,15,16.
Several studies comparing healthcare resource utilization and
associated costs between LAIs and OATs and costs of LAIs
with OATs have shown the beneficial effects of LAIs, such as
reduced hospitalizations, as well as better economic and clin-
ical outcomes17–21.
The LAI paliperidone palmitate (PP1M) is a once-per-month
injectable agent approved by the FDA in 2009 for the treat-
ment of schizophrenia and in 2014 for schizoaffective disor-
ders in adults22. Since PP1M is administered by a health care
provider and can be administered less frequently than OATs,
patients may be more likely to adhere to the medication,
resulting in improved symptom control, relapse prevention
and overall improvement in disease burden. According to
studies conducted in Greece, Norway, and Sweden, PP1M has
been shown to be a cost effective option compared to other
LAIs and OATs23–25. A recent study in the US among Veterans
Affairs patients with schizophrenia treated with PP1M or OATs
suggested that inpatient admission rates and associated costs
were lower among those treated with PP1M26. The generaliz-
ability of these studies’ results may be limited due to different
study designs, settings, or populations.
There are a limited number of real-world studies that have
compared LAIs to OATs among Medicaid beneficiaries with
schizophrenia. This study used a propensity-score matched
PSM cohort design to compare all-cause health care utiliza-
tion and costs of PP1M with atypical OATs. Results from this
study should provide real-world comparative economic evi-
dence which may in turn prove helpful to health care profes-
sionals in supporting the value of LAIs such as PP1M
compared to atypical OATs.
Methods
Data source
This was a retrospective cohort study using health insurance
claims from the Medi-Cal database, which provides informa-
tion regarding outpatient care, inpatient care, and prescrip-
tion drugs for low-income and disabled California residents.
The Medi-Cal paid claims files include institutional claims,
professional service claims, and pharmacy claims. Service
claims include the date, type, place, and units (days) of ser-
vice; paid and billed amount; primary and secondary
diagnosis codes; and provider identification. The pharmacy
claims include the national drug code, fill date, days of sup-
ply, paid and billed amount, and quantity. Eligibility files con-
sist of enrollment status for each month and enrollees’
demographic information. The study period, 1 July 2008 to
31 December 2014, was based on the US Food and Drug
Administration’s approval of PP1M in 2009 and the study
requirement of at least a 12 month baseline period. Data was
collected from Medi-Cal paid claims and eligibility files for
Medi-Cal enrollees.
Study population
To be eligible for this study, patients were required to have
2 diagnostic claims for schizophrenia (International
Classification of Diseases, 9th Revision, Clinical Modification
[ICD-9-CM] code: 295.xx) during the study period, and have
evidence of 2 claims for PP1M or the same atypical OAT
(aripiprazole, asenapine, iloperidone, lurasidone, olanzapine
[including combination olanzapine/fluoxetine], paliperidone,
quetiapine, risperidone or ziprasidone) within 60 days of
each other during the identification period (1 July 2009 to 31
December 2013). The initiation date of the first PP1M or OAT
prescription was designated as the index date. OAT patients
were required to have no evidence of a PP1M injection dur-
ing the 12 months pre-index date (baseline period) and no
claims for their index OAT prescription for 6 months pre-
index date.
Eligible patients were required to be 18 years of age,
have continuous health plan enrollment for the 12 month
baseline period and 12 months after the index date (follow-
up period), no more than one prescription for any LAI anti-
psychotic between the first two index medications, and no
prescription for clozapine during the study period, since
Clozapine it is indicated for treatment of severely ill patients
with schizophrenia who fail to respond adequately to stand-
ard antipsychotic treatment. Antipsychotic-naïve patients (no
prescription for any atypical or typical OAT or LAI) during the
12 month baseline period were excluded from the analysis.
Therefore, PP1M cohort patients may have had claims for
OAT or LAI antipsychotics at any point during the study
period. In order to ensure the thoroughness of the medica-
tion claims histories, patients with dual eligibility were also
excluded. Patients were assigned to one of two mutually
exclusive cohorts, the PP1M cohort or the OAT cohort,
depending on their index antipsychotic medication.
Study variables
During the 12 month baseline period, demographics (age
and gender), clinical characteristics (schizophrenia subtype,
prior psychiatric medications use, polypharmacy [2 OAT
prescriptions or administrations with an overlap of 60 days],
comorbidities such as mental and general health conditions,
antipsychotic medication proportion of days covered [PDC]),
and economic variables (all-cause health care utilization and
costs) were recorded. PDC was calculated for any and all anti-
psychotics in the pre-index period and determined as the
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number of days covered by medication divided by the total
days during the baseline period. The number of patients with
a PDC of 0.00–0.50, 0.51–0.80 and 0.81–1.00 were also
reported. Patients with a PDC gap of >30 days were also
flagged.
During the follow-up period, antipsychotic treatment pat-
terns and all-cause health care utilization and costs were cap-
tured for both the PP1M and OAT cohort. Treatment patterns
included discontinuation (30 day gap in index treatment
therapy), persistence (30 day gap between prescriptions),
PDC (number of days covered by index medication/total days
in the follow-up period), and switching (a pharmacy claim for
a new medication within 90 days post-index therapy discon-
tinuation). Time to discontinuation (in days) was also
recorded. All-cause follow-up ambulatory (office and out-
patient), emergency room (ER), inpatient, and pharmacy vis-
its, as well as associated annual costs, were recorded.
Hospitalization, length of stay (LOS), and total costs (inpa-
tientþ outpatientþpharmacy) during the 12 month follow-
up period were also recorded.
Statistical analysis
For the total study population, all measures including the
patient’s demographic and clinical characteristics, treatment
patterns, all-cause health care utilization, and associated costs
during the 12 month follow-up period were reported descrip-
tively by the two treatment cohorts. Chi-square tests were
used to evaluate the statistical significance of differences for
categorical variables, and Student’s t-tests were used to
assess differences in the mean of continuous variables. The
level of significance was set to a¼ 0.05.
In order to determine the association of baseline variables
with treatment cohorts, an unconditional stepwise logistic
regression model was built that incorporated potential pre-
dictors of therapy as independent variables in the regression
and group status (e.g. PP1M cohort vs. OAT cohort) as the
outcome. A propensity score was then calculated for each
study-qualified patient to represent the likelihood of receiv-
ing PP1M based on the patient’s baseline data and to minim-
ize the potential of confounding factors. Each patient in the
PP1M cohort was matched 1:1 to a patient in the OAT cohort
using greedy match method27 within 0.001 units of the pro-
pensity score while controlling for the covariates age, gender,
comorbidities (bipolar disorder, any depression disorder,
attention deficit hyperactivity disorder, panic disorder, anx-
iety, suicide attempt and intentional injuries, substance abuse
and alcohol abuse, diabetes, obesity), schizophrenia subtype,
prior antipsychotic treatment PDC, and pre-index all-cause
health care utilization. The quality of the match was assessed
using descriptive statistics and visual inspection of the pro-
pensity score histograms (Figure 1). The highest-quality
match showed no significant differences in baseline charac-
teristics and fully congruent propensity histograms for the
matched cohorts. All-cause health care utilization and cost
outcomes were then compared between the matched
cohorts using chi-square and t-tests for categorical and
continuous variables, respectively. There were no adjustments
made for multiplicity.
Results
There were a total of 23,511 patients with 2 diagnostic
claims for schizophrenia (PP1M cohort: 2666; OAT cohort:
20,845). After applying inclusion and exclusion criteria, there
were 1939 patients in the PP1M cohort and 3786 patients in
the OAT cohort (total n¼ 5725).
Baseline patient characteristics
The average age of OAT patients was higher than that of
PP1M patients (42.9 vs. 40.7 years, p< .001). A lower propor-
tion of OAT patients were male compared to PP1M patients
(49.7% vs. 57.0%, p< .001). PP1M and OAT patients were
similar with respect to schizophrenia sub-types (catatonic
and paranoid type: 32.1% vs. 30.1%, p¼ .108; schizoaffective
disorder: 36.0% vs. 35.5%, p¼ .709; other types: 31.9% vs.
34.4%, p¼ .051).
The Charlson Comorbidity Index (CCI) score was slightly
higher among OAT patients than PP1M patients (0.5 vs. 0.4,
p< .001), indicating a population with a higher degree of
medical comorbidity. Compared to OAT patients, a signifi-
cantly higher proportion of PP1M patients had other mental
health disorders (57.6% vs. 51.0%, p< .001), including bipolar
disorder (13.9% vs. 11.8%, p¼ .022) and substance or alcohol
abuse (10.7% vs. 5.3%, p< .001), and a significantly lower
proportion of patients had panic disorder (0.4% vs. 1.0%,
p¼ .022) (Table 1). There was also a significant difference in
baseline all-cause health care utilization and costs (Table 1).
The number of unique antipsychotic medications in the base-
line period was significantly higher among patients in the
PP1M cohort (2.3 vs. 1.4, p< .001) and a significantly higher
proportion of patients in the PP1M cohort showed evidence
of polypharmacy (20.7% vs. 4.4%, p< .001; data not shown).
Matching
The propensity score matching resulted in well matched
PP1M and OAT cohorts, each consisting of 722 patients.
Patients in these cohorts appeared well matched with respect
to mean age (40.4 years vs. 41.2 years, p¼ .206), gender
(54.2% vs. 55.0% males, p¼ .751), clinical characteristics, base-
line psychiatric medications, PDC, select comorbidities, and
baseline all-cause health care utilization and costs (all p> .05;
Table 1). The only significant difference observed among the
post-matched cohorts was the number of patients with PDC
0–0.50 (45.8% vs. 40.3%, p¼ .034, Table 1).
Outcomes
During the 12 month follow-up period, PP1M patients were
significantly less likely to discontinue treatment (30.6% vs.
39.5%, p< .001) or switch therapies (21.6% vs. 27.7%,
p¼ .007), had better persistence (69.4% vs. 60.5%, p< .001),
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and had a higher mean PDC (0.7 vs. 0.6, p< .001) compared
to OAT patients (Table 2).
A lower proportion of PP1M patients had any inpatient
visit (61.6% vs. 77.4%, p< .001), any outpatient ER visit
(49.0% vs. 56.0%, p¼ .008), or any other outpatient hospital
visit (78.8% vs. 89.6%, p< .001) compared with OAT patients.
Additionally, compared with OAT-treated patients, PP1M
patients had fewer mean hospitalization days (15.0 vs. 27.7
days, p< .001), mean inpatient visits (5.0 vs. 7.9, p< .001),
mean outpatient ER visits (2.1 vs. 2.9, p¼ .016), and other
outpatient hospital visits (13.1 vs. 16.2, p¼ .004) (Table 2,
Figure 2).
While mean annual pharmacy costs were significantly
higher among PP1M patients ($16,347 vs. $9115, p< .001),
the PP1M cohort incurred significantly lower inpatient visit
costs ($5060 vs. $10,880, p< .001), outpatient ER visit costs
($379 vs. $547, p¼ .021), outpatient office visit costs ($997 vs.
$1412, p¼ .012), and other outpatient hospital costs ($2763
vs. $3353, p¼ .019) compared to OAT patients. Total health
care costs were not significantly different between the PP1M
and OAT cohorts ($25,546 vs. $25,307, p¼ .853) (Table 2,
Figure 3).
Discussion
This real-world comparative effectiveness study compared
the all-cause health care utilization and associated costs
between patients with schizophrenia treated with OATs and
Figure 1. Propensity score distribution for study qualified and propensity score matched cohorts. (a) Before matching. (b) After matching.
OAT: Oral atypical antipsychotics; PP (please change to PP1M): Paliperidone Palmitate Once-Monthly.
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Table 2. Clinical outcomes, health care utilization and costs for matched PP1M and OAT cohorts (12 month follow-up period).
PP1M Cohort (N¼ 722) OAT Cohort (N¼ 722)
N/Mean %/SD N/Mean %/SD p-Value STD
Clinical Outcomes
Discontinuation 221 30.6% 285 39.5% <.001 18.6
Time to discontinuation 139.1 87.0 133.9 87.1 .503 6.0
Persistence 501 69.4% 437 60.5% <.001 18.6
PDC 0.7 0.3 0.6 0.3 <.001 26.8
Switching 156 21.6% 200 27.7% .007 14.2
Follow-up All-cause Health Care Utilization
Any inpatient visit 445 61.6% 559 77.4% <.001 34.8
Any outpatient ER visit 354 49.0% 404 56.0% .008 13.9
Any outpatient office visit 602 83.4% 618 85.6% .245 6.1
Any other outpatient visit 569 78.8% 647 89.6% <.001 29.9
Any pharmacy visit 722 100.0% 722 100.0% 0.0
Hospitalization days, n 15.0 45.8 27.7 60.2 <.001 23.8
Inpatient visits, n 5.0 8.8 7.9 10.8 <.001 30.2
Outpatient ER visits, n 2.1 5.6 2.9 7.1 .016 12.7
Outpatient office visits, n 9.6 25.3 11.2 23.6 .196 6.8
Other outpatient visits, n 13.1 15.0 16.2 24.3 .004 15.2
Pharmacy visits, n 30.6 19.2 30.7 21.6 .932 0.4
Follow-up All-cause Health Care Costs
Inpatient visit costs $5060 $14,036 $10,880 $25,061 <.001 28.7
Outpatient ER visit costs $379 $1253 $547 $1500 .021 12.1
Outpatient office visit costs $997 $2131 $1412 $3896 .012 13.2
Other outpatient costs $2763 $4278 $3353 $5247 .019 12.3
Pharmacy costs $16,347 $8578 $9115 $6760 <.001 93.6
Total (outpatientþ inpatientþ pharmacy) costs $25,546 $18,589 $25,307 $29,154 .853 1.0
OAT: oral antipsychotic therapy; PP1M: paliperidone palmitate once monthly; SD: standard deviation; STD: standardized difference; PDC:
Proportion of days covered; ER: Emergency Room.
Figure 2. All-cause health care utilization of matched PP1M and OAT cohorts. PP1M: paliperidone palmitate once monthly; OAT: oral antipsychotic therapy; ER:
emergency room.
Figure 3. All-cause health care costs of matched PP1M and OAT cohorts. PP1M: paliperidone palmitate once monthly; OAT: oral antipsychotic therapy; ER: emer-
gency room.
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those treated with PP1M. To the best of our knowledge, this
is the first study which compares the treatment patterns (dis-
continuation, persistence, switching), all-cause health care
utilization, and costs among patients prescribed PP1M or
OATs in the Medi-Cal population.
Previous large, randomized controlled trials have reported
high antipsychotic discontinuation rates among patients with
schizophrenia7,28. A non-randomized study conducted by
Tiihonen et al. reported that 54% of 2588 patients with
schizophrenia discontinued their antipsychotic treatment dur-
ing the first 30 days after hospital discharge15. Despite high
overall discontinuation rates among this population, the pair-
wise comparison between LAIs and their equivalent oral for-
mulations showed that LAIs were associated with a
significantly lower risk of discontinuation15. The results of our
study are consistent with the above-mentioned study as well
as other previous studies, suggesting that the patients pre-
scribed PP1M had significantly lower discontinuation, switch-
ing rates, and non-adherence (calculated by PDC) compared
to those prescribed OATs29,30. High discontinuation rates
among OAT cohort patients may be due to a lack of motiv-
ation and cooperation, or the frequent daily administration
of the drug compared to PP1M patients who visit a health
care professional once a month for the drug administra-
tion10,15,17,31. Greater adherence to LAI therapy helps physi-
cians make beneficial decisions and distinguishes compliance
failure from efficacy failure, which can help to prevent the
switching of medications15,30.
Results from our descriptive analysis demonstrated that
baseline characteristics differed among patients who were
initiated on PP1M versus those on OATs. Some notable differ-
ences between the PP1M and OAT cohorts’ baseline charac-
teristics included the proportion of patients with evidence of
polypharmacy, number of unique antipsychotic medications
as well as all-cause health care utilization and costs. Thus,
PSM is an effective methodology to control for baseline dif-
ferences. After comparing the well matched cohorts, the cur-
rent study found that patients in the PP1M cohort had
significantly fewer all-cause inpatient, outpatient ER, and out-
patient visits compared to those who initiated OATs. While
these differences led to lower associated inpatient, outpatient
ER, outpatient office, and outpatient costs, the PP1M cohort
had higher mean pharmacy costs, resulting in similar total
all-cause total costs between cohorts. Although PP1M was
observed to be associated with higher pharmacy costs vs.
OATs, it is important to keep in mind the current study
applied pharmacy costs without considering rebates, thus it
is likely that Medi-Cal would experience cost savings associ-
ated with PP1M use after pharmacy rebates are considered.
Our results are consistent with two previous studies compar-
ing health care costs and utilization among patients with
schizophrenia who were on PP1M or OATs10,26. A study con-
ducted among Medicaid-covered patients with schizophrenia
suggested that patients who initiated treatment with a LAI
had overall reduced hospitalizations, LOS, and hospital
charges, better medication adherence, and lower utilization
of health services11. Results from this study reported out-
comes among all LAIs; however, our study reported exclu-
sively on PP1M. Previous studies have reported that
the prescription of LAIs is associated with a 50–65%
decrease in the length of inpatient stay and a lower risk of
re-hospitalizations leading to better global outcomes6,15,24.
Despite the advantages of LAI antipsychotics associated
with lower costs and hospitalizations compared to OATs,
there are several barriers to the utilization of LAIs in the
United States, such as negative attitudes of health care pro-
fessionals, treatment settings, and insurance coverage32,33.
Also, patient-related factors such as pain of injection, fear of
loss of autonomy, and reluctance contribute to the lower util-
ization of these LAIs34. The unavailability of experienced
health care professionals may also contribute to the limited
outpatient use of LAIs. The results from our study, along with
consistent results from previous studies, should help high-
light the advantages of LAIs over OATs; the adherence
advantage is especially noteworthy, as long treatment dur-
ation is a major driver of better clinical and functional out-
comes in the long-term treatment of patients with
schizophrenia29. Lower use of inpatient services is also a key
advantage of LAIs over OATs since it provides economic
benefit which is a key factor from the payers’ perspective26.
The results of our study should be interpreted within the
context of several limitations. Given that this was an analysis
of claims data, inherent limitations of claims database analy-
ses need to be considered: these include unavailability of
clinical measures, the possibility of information bias due to
coding errors, and lack of generalizability beyond the popula-
tion studied. Treatment selection bias, which is clearly
depicted in the histogram (Figure 1), shows the likelihood of
patients in each of the cohorts to be treated with PP1M.
According to the histogram, patients in the OAT cohort were
less likely to receive a PP1M treatment. Therefore, through
application of the propensity score matching approach using
a greedy matching method, patients in the PP1M cohort
were successfully matched to those in the OAT cohort result-
ing in similar distribution of individual probabilities of receiv-
ing PP1M. The other limitation of this study is that we only
compared one LAI, PP1M, with other OATs. Since the main
focus of our study was to help health care professionals
understand the value of PP1M rather than LAIs in general,
interpretations should be made cautiously.
This study contributes valuable information10,35–37. Future
studies should be conducted to compare all LAIs and OATs
while considering direct and indirect sources of health care
utilization and costs. Raising awareness regarding the bene-
fits of using LAIs is necessary in order to reduce relapses and
improve health-related quality of life for patients with
schizophrenia.
Conclusion
This large database analysis demonstrated that patients with
schizophrenia treated with PP1M had fewer mean annual
hospitalizations and shorter mean LOS compared to a
matched cohort of patients treated. Patients who were
treated with PP1M had a lower rate of discontinuations and
index drug switches, better persistence, and higher PDC.
Patients who were treated with PP1M also had significantly
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fewer inpatient, ambulatory, and ER visits. Although phar-
macy costs were significantly higher among PP1M patients,
there was no difference in total annual health care costs
between PP1M and PAT patients among the PP1M and OAT
cohort patients.
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Notes
1. Invega Sustenna is a registered trade name of Janssen Pharmaceuticals,
Inc Titusville, NJ
2. Risperdal Consta (Janssen Pharmaceuticals, Inc., Titusville, NJ)
3. Zyprexa Relprevv (Eli Lilly & Co, Indianapolis, IN)
4. Abilify (Otsuka America Pharmaceutical, Inc, Rockville, MD )
5. Haldol (various), and Prolixin (various)
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